Taiwanese President Tsai Ing-wen received her first dose of the coronavirus vaccine developed on the island on Monday, launching its deployment to the public.
The vaccine, manufactured by Medigen Vaccine Biologics Corp., was urgently approved by regulators in July using a shortcut that met with stiff opposition from parts of Taiwan’s medical and scientific community, AP reports.
Taiwanese regulators have bypassed the large-scale, longer-term studies that are typically used to approve vaccines. Instead, they compared the level of antibodies Medigen’s vaccine was able to generate with that of AstraZeneca’s vaccine, which has been approved by many governments and has undergone the full three stages of clinical trials.
The two-dose Medigen protein subunit vaccine uses a piece of the coronavirus to train the body to trigger an immune response.
Tsai received his first dose of the vaccine Monday morning at a gymnasium at National Taiwan University in Taipei.
As of Friday, 40% of Taiwan’s 23 million people had received at least one dose of a Covid vaccine. The island’s vaccination policy is to prioritize the first vaccines, with only the most-at-risk groups initially receiving the two full doses, such as medical workers.
This is a big jump from May, when less than 5% of the population received a vaccine.